CIBC Private Wealth Group LLC Sells 9,265 Shares of Revvity, Inc. (NYSE:RVTY)

CIBC Private Wealth Group LLC lowered its stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 293,614 shares of the company's stock after selling 9,265 shares during the period. CIBC Private Wealth Group LLC owned about 0.24% of Revvity worth $34,183,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Cerity Partners LLC grew its holdings in Revvity by 7.4% in the third quarter. Cerity Partners LLC now owns 17,130 shares of the company's stock valued at $2,188,000 after purchasing an additional 1,174 shares during the last quarter. FMR LLC increased its holdings in Revvity by 40.8% during the 3rd quarter. FMR LLC now owns 155,556 shares of the company's stock valued at $19,872,000 after acquiring an additional 45,040 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Revvity by 23.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,805 shares of the company's stock valued at $4,830,000 after purchasing an additional 7,237 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Revvity by 7.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 684,078 shares of the company's stock valued at $87,391,000 after purchasing an additional 48,700 shares during the last quarter. Finally, Public Sector Pension Investment Board lifted its stake in Revvity by 14.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 5,383 shares of the company's stock valued at $688,000 after buying an additional 700 shares in the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Transactions at Revvity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the transaction, the insider now owns 33,400 shares of the company's stock, valued at $4,232,782. This represents a 31.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Tajinder S. Vohra sold 5,492 shares of the business's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the sale, the insider now directly owns 19,652 shares in the company, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their position. The disclosure for this sale can be found here. 0.68% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on RVTY shares. Bank of America raised Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price objective on the stock in a research note on Friday, December 13th. KeyCorp upped their price objective on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Barclays lifted their price objective on Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Raymond James reaffirmed an "outperform" rating and set a $145.00 price objective (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Finally, Sanford C. Bernstein lowered shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective for the company. in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Revvity has a consensus rating of "Moderate Buy" and a consensus price target of $136.25.

Revvity Trading Down 5.0 %

Shares of RVTY stock traded down $5.33 on Thursday, reaching $101.39. The company had a trading volume of 541,949 shares, compared to its average volume of 874,528. The stock has a market cap of $12.18 billion, a PE ratio of 45.86, a PEG ratio of 3.82 and a beta of 1.06. The company has a 50-day moving average of $114.20 and a 200-day moving average of $116.84. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. Revvity, Inc. has a 12 month low of $97.32 and a 12 month high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last issued its earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the prior year, the firm earned $1.25 earnings per share. On average, equities analysts forecast that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.28%. Revvity's dividend payout ratio (DPR) is currently 12.67%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.